P
Pierre Saintigny
Researcher at Claude Bernard University Lyon 1
Publications - 164
Citations - 5652
Pierre Saintigny is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 33, co-authored 129 publications receiving 4299 citations. Previous affiliations of Pierre Saintigny include Centre national de la recherche scientifique & University of Paris.
Papers
More filters
Journal ArticleDOI
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai T. Tran,Robert J. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy L. Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun Ki Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach +33 more
TL;DR: A robust EMT signature is developed that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance associated with the mesenchyal phenotype.
Journal ArticleDOI
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle,Lauren Averett Byers,Edward S. Kim,Pierre Saintigny,J. Jack Lee,George R. Blumenschein,Anne Tsao,Suyu Liu,Jill E. Larsen,Jing Wang,Lixia Diao,Kevin R. Coombes,Lu Chen,Shuxing Zhang,Mena Abdelmelek,Ximing Tang,Vassiliki A. Papadimitrakopoulou,John D. Minna,Scott M. Lippman,Waun Ki Hong,Roy S. Herbst,Ignacio I. Wistuba,John V. Heymach,Garth Powis +23 more
TL;DR: Molecular modeling studies showed that different conformations imposed by mutant KRas may lead to altered association with downstream signaling transducers, and implies that therapeutic interventions may need to take into account the specific mutants expressed by the tumor.
Journal ArticleDOI
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James W. Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach +27 more
TL;DR: SCLC was significantly more sensitive to PARP inhibitors than were NSCLCs, and PARP inhibition downregulated key components of the DNA repair machinery and enhanced the efficacy of chemotherapy.
Journal ArticleDOI
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon,Jean-Charles Soria,Raanan Berger,Wilson H. Miller,Eitan Rubin,Aleksandra Kugel,Apostolia Maria Tsimberidou,Pierre Saintigny,Aliza Ackerstein,Irene Brana,Yohann Loriot,Mohammad Afshar,Vincent A. Miller,Fanny Wunder,Catherine Bresson,Jean-Francois Martini,Jacques Raynaud,John Mendelsohn,Gerald Batist,Amir Onn,Josep Tabernero,Richard L. Schilsky,Vladimir Lazar,J. Jack Lee,Razelle Kurzrock +24 more
TL;DR: This study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment, and shows promise in improving clinical outcomes.
Journal ArticleDOI
New insights into the role of EMT in tumor immune escape
Stéphane Terry,Pierre Savagner,Sandra Ortiz-Cuaran,Linda Mahjoubi,Pierre Saintigny,Jean Paul Thiery,Jean Paul Thiery,Jean Paul Thiery,Salem Chouaib +8 more
TL;DR: Current knowledge of how cellular heterogeneity and plasticity could be involved in shaping the tumor microenvironment (TME) and in controlling antitumor immunity is reviewed.